» Non-Financial

Company Directors
Company Advisors
New & Press Releases
Directors Share Dealings
Major Shareholders
Company Subsidiary Calendar of Future Events
Company Name Change
Company Status Change

» Analyst Spreadsheet

Quick View(PDF)
Trader(PDF)
Dossier(PDF)
Download Analyst Template
Analyst Spreadsheet
Download Master Template
Annual Master Spreadsheet
Quarterly Master Spreadsheet
Annual & Quaterly Master Spreadsheet
Valuation Model Template
Valuation Model Spreadsheet
Business Risk(PDF)
Credit Metrics(PDF)
Annual Reports

For all products and/or service inquiries or to learn more about how WVB customer service solutions can reduce your service costs while increasing customer satisfaction, email us at .

DERMTECH

WVB Number : VGB000040128 Country : British Virgin Islands
SIC categorization : MEDICAL LABORATORIES (8071) ISIN : VGG2379F1080, VGG2379F1163
FT categorization : BUSINESS SERVICES (481)  
Company status: ACTIVE  

» Corporation Profile :

Profile in brief:
The Company is an emerging growth molecular diagnostic company developing and marketing its Clinical Laboratory Improvement Amendments of 1988 laboratory services including molecular pathology tests to facilitate the diagnosis of dermatologic conditions including melanoma. The Company has developed a proprietary, non-invasive technique for sampling the surface layers of the skin using an adhesive patch in order to collect individual biological information for commercial applications in the medical diagnostic field.
Phone : 1 561 404 9034 Fax :
Chairman: : RAJIV SHUKLA Auditor : KPMG LLP
CEO/Managing Director : RAJIV SHUKLA

» Company Facts

Net Profit Margin (%) -598.96  
Operating Margin (%) -598.96  
Return on Assets (%) -80.12  
Return on Equity (%) -92.79  
Employees 118  

» Company Financials

  Annual (2020)
Income Statement
('000 USD )
Sales/Total Revenue 5,885  
EBITDA -34,803  
EBIT -35,289  
Net Income -35,249  
Balance Sheet
( '000 USD)
Total Current Assets 66,882  
Total Assets 69,780  
Current Liabilities 5,425  
Total Liabilities & Debt 6,290  
Total Equity 63,490  
Cash & Flow
( '000 USD)
Net Income/Staring Line -35,249  
Cash from Operating -28,684  
Cash from Investing -41,340  
Cash from Financing 78,898  
Cash & Equivalent Yr End 24,248